- Home
- BTOC vs BTAI Comparison
BTOC vs BTAI Comparison
Compare BTOC & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTOC | BTAI |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.6M | 49.2M |
| IPO Year | 2024 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BTOC | BTAI |
|---|---|---|
| Price | $0.63 | $2.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | ★ 1.4M | 661.6K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $197,399,541.00 | $752,000.00 |
| Revenue This Year | $34.89 | N/A |
| Revenue Next Year | $14.53 | $416.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.35 | N/A |
| 52 Week Low | $0.41 | $1.17 |
| 52 Week High | $6.10 | $9.26 |
Technical Indicators
Market Signals| Indicator | BTOC | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 53.44 | 51.76 |
| Support Level | $0.56 | $1.82 |
| Resistance Level | $0.62 | $2.33 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 86.29 | 62.87 |
Price Performance
Historical ComparisonAbout BTOC Armlogi Holding Corp. Common Stock
Armlogi Holding Corp is a fast-growing U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions relating to warehouse management and order fulfillment. The company provides one-stop warehousing and logistics services to cross-border e-commerce merchants outside the U.S. who seek to sell in the U.S. market. The warehouses are equipped with automated sorting systems, heavy-duty forklifts, and pallets and trays that are suitable for processing bulky items. The services of the company include customs brokerage services, transportation of merchandise to U.S. warehouses, and warehouse management and order fulfillment services.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.